TITLE

Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease

AUTHOR(S)
Hindorf, U.; Lindqvist, M.; Peterson, C.; Söderkvist, P.; Ström, M.; Hjortswang, H.; Pousette, A.; Almer, S.
PUB. DATE
October 2006
SOURCE
Gut;Oct2006, Vol. 55 Issue 10, p1423
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Firm recommendations about the way thiopurine drugs are introduced and the use of thiopurine methyltransferase (TPMT) and metabolite measurements during treatment in inflammatory bowel disease (IBD) are lacking. Aim: To evaluate pharmacokinetics and tolerance after initiation of thiopurine treatment with a fixed dosing schedule in patients with IBD. Patients: 60 consecutive patients with Crohn's disease (n = 33) or ulcerative colitis (n = 27) were included in a 20 week open, prospective study. Methods: Thiopurine treatment was introduced using a predefined dose escalation schedule, reaching a daily target dose at week 3 of 2.5 mg azathioprine or 1.25 mg 6-mercaptopurine per kg body weight. TPMT and ITPA genotypes, TPMT activity, TPMT gene expression, and thiopurine metabolites were determined. Clinical outcome and occurrence of adverse events were monitored. Results: 27 patients completed the study per protocol, while 33 were withdrawn (early protocol violation (n = 5), TPMT deficiency (n = 1), thiopurine related adverse events (n = 27)); 67% of patients with adverse events tolerated long term treatment on a lower dose (median 1.32 mg azathioprine/kg body weight). TPMT activity did not change during the 20 week course of the study but a significant decrease in TPMT gene expression was found (TPMT/huCYC ratio; p = 0.02). Patients with meTIMP concentrations >11 450 pmol/8×108 red blood cells during steady state at week 5 had an increased risk of developing myelotoxicity (odds ratio = 45.0; p = 0.015). Conclusions: After initiation of thiopurine treatment using a fixed dosing schedule, no general induction of TPMT enzyme activity occurred, though TPMT gene expression decreased. The development of different types of toxicity was unpredictable, but we found that measurement of meTIMP early in the steady state phase helped to identify patients at risk of developing myelotoxicity.
ACCESSION #
22659585

 

Related Articles

  • A 6-Thioguanine Nucleotide Threshold Level of 400 pmol/8 × 108 Erythrocytes Predicts Azathioprine Refractoriness in Patients With Inflammatory Bowel Disease and Normal TPMT Activity. Roblin, Xavier; Biroulet, Laurent P.; Phelip, Jean M.; Nancey, Stéphane; Flourie, Bernard // American Journal of Gastroenterology;Dec2008, Vol. 103 Issue 12, p3115 

    BACKGROUND AND AIMS: A therapeutic level of 6-thioguanine nucleotides (6-TGN) has been reported in inflammatory bowel disease (IBD) patients under azathioprine (AZA). We investigated the threshold value of 6-TGN that may be predictive of AZA refractoriness and its impact on safety...

  • A Search for the Optimal Duration of Treatment with 6-Mercaptopurine for Ulcerative Colitis. Lobel, Efrat Z.; Korelitz, Burton I.; Xuereb, Mark A.; Panagopoulos, Georgia // American Journal of Gastroenterology;Mar2004, Vol. 99 Issue 3, p462 

    BACKGROUND AND AIMS: 6-mercaptopurine has proven to be effective in the treatment and maintenance of remission of ulcerative colitis (UC). The optimal duration of treatment with 6-MP is unknown. The intention of this study was to determine the best duration of treatment with 6-MP in terms of...

  • Steering Azathioprine Safely: Lessons From Pharmacogenetics. Aithal, Guruprasad P.; Hoffman, Brenda J.; Johnson, David // American Journal of Gastroenterology;Nov2001, Vol. 96 Issue 11, p3202 

    The immunosuppressive properties of azathioprine and 6-mercaptopurine are mediated by their active metabolite 6-thioguanine. Cuffari and colleagues performed a prospective study to determine the relationship of erythrocyte 6-thioguanine levels and treatment efficacy in adult patients with...

  • Recent Indications and Methods of Surgery for Inflammatory Bowel Disease. S. Ohki; S. Terashima; K. Sekikawa; S. Takenoshita; M. Gotoh // Current Drug Targets - Inflammation & Allergy;Jun2003, Vol. 2 Issue 2, p113 

    Inflammatory bowel disease, notably ulcerative colitis (UC) or Crohn disease (CD), is basically benign, but sometimes develops into serious or fatal cancer. While the primary therapies are medical, such as pharmacotherapy and dietetic modification, intractable, serious, and cancerous cases can...

  • Ulcerative colitis. Ghosh, Subrata // BMJ: British Medical Journal (International Edition);04/22/2000, Vol. 320 Issue 7242, p1119 

    Provides information on ulcerative colitis. Clinical features and diagnosis; Etiology; Clinical management; Failure of medical management and its indications for surgery.

  • What's new in inflammatory bowel disease in 2008? Baumgart, Daniel C. // World Journal of Gastroenterology;1/21/2008, Vol. 14 Issue 3, p329 

    Ulcerative colitis and Crohn's disease represent the two major forms of inflammatory bowel disease. In this highlight topic series of articles we cover the latest developments in genetics and epidemiology, intestinal physiology, mucosal immunology, mechanisms of epithelial cell injury and...

  • PREVALENCE AND MANAGEMENT OF INFLAMMATORY BOWEL DISEASE: DATA FROM PRIMARY CARE RECORDS, INCLUDING 5-ASA PRESCRIBING AND COMPLIANCE. Stone, M.A.; Mayberry, J.F.; Baker, R.B. // Gut;Apr2003 Supplement 1, Vol. 52, pA68 

    Background: Data from general practice (GP) records in North Tees (Rubin et al, 2000) suggested a higher prevalence of inflammatory bowel disease (IBD) than previous estimates from hospital data. Regular prescribing of 5-aminosalicylic acid (5-ASA) therapy can reduce the risk of colorectal...

  • High Resolution Melting Curve Analysis for High-Throughput SNP Genotyping in IL23R Gene and Association of IL23R with Slovenian Inflammatory Bowel Diseases Patients. Mitrovič, Mitja; Potočnik, Uroš // Acta Chimica Slovenica;2010, Vol. 57 Issue 2, p498 

    Single nucleotide polymorphism (SNP) analysis is important tool in the studies of genetic factors associated with complex diseases and with genetically influenced response to drug therapy (pharmacogenetics). Recently, a new generation of generic dsDNA binding dyes (LCGreenâ„¢) contributed to...

  • Characterization of Inflammatory Bowel Disease With Urinary Metabolic Profiling. Williams, Horace R. T.; Cox, I. Jane; Walker, David G.; North, Bernard V.; Patel, Venisha M.; Marshall, Sara E.; Jewell, Derek P.; Ghosh, Subrata; Thomas, Huw J. W.; Teare, Julian P.; Jakobovits, Simon; Zeki, Sebastian; Welsh, Kenneth I.; Taylor-Robinson, Simon D.; Orchard, Timothy R. // American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1435 

    OBJECTIVES:Distinguishing between the inflammatory bowel disease (IBD), Crohn's disease (CD), and ulcerative colitis (UC) is important for both management and prognostic reasons. Discrimination using noninvasive techniques could be an adjunct to conventional diagnostics. Differences have been...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics